Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI:10.1007/s11912-024-01628-0

Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney

{"title":"Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.","authors":"Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney","doi":"10.1007/s11912-024-01628-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.Recent findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures. In this new frontier, translational efforts are underway to personalize the use of ADCs, including refining HER2 quantification and elucidating genetic, epigenetic, and post-translational mechanisms of resistance. ADCs have provided important treatment options for patients with breast cancer. As patients become eligible for more than one ADC, there is an unmet need to identify the appropriate timing and sequence of these therapies to maximize their efficacy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"68-79"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01628-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.

Recent findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures. In this new frontier, translational efforts are underway to personalize the use of ADCs, including refining HER2 quantification and elucidating genetic, epigenetic, and post-translational mechanisms of resistance. ADCs have provided important treatment options for patients with breast cancer. As patients become eligible for more than one ADC, there is an unmet need to identify the appropriate timing and sequence of these therapies to maximize their efficacy.

查看原文本刊更多论文

乳腺癌中的抗体-药物偶联物：通往生物学知情选择和测序的道路。

综述目的：在这篇综述中，我们讨论了支持在乳腺癌治疗中使用抗体-药物偶联物（ADC）的证据，描述了新的ADC和正在开发的联合方案，并检查了我们目前对耐药机制和生物标志物的理解，以指导ADC的选择和测序。最近的研究发现：三种adc已被证明对转移性乳腺癌患者有益：曲妥珠单抗emtansine (T-DM1)，曲妥珠单抗deruxtecan （T-DXd）和sacituzumab govitecan （SG）。随着临床前研究工作的开展，有超过200种研究性ADC正在进行中，以确定新的ADC靶点和结构。在这一新的前沿领域，翻译工作正在进行，以个性化adc的使用，包括改进HER2定量和阐明遗传、表观遗传和翻译后耐药机制。adc为乳腺癌患者提供了重要的治疗选择。由于患者有资格接受一种以上的ADC，因此需要确定这些治疗的适当时间和顺序，以最大限度地提高其疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.